TOLUNA
6.4.2022 11:02:14 CEST | Business Wire | Press release
Toluna, the leading consumer insights provider and parent company of Harris Interactive and KuRunData, today announced a joint initiative with Harris Interactive in service of the French Presidential and Legislative elections.
The companies are conducting weekly polling to measure French citizens on their preferred candidates, voting intention, and out-of-polling-station results. Harris Interactive has historically led this polling effort. However, this year, Harris Interactive is officially partnering with its sister company, Toluna, to cover the events. This year’s efforts include over 50 pre-election surveys with over 100,000 people interviewed, as well as 5,000 interviews on election day.
Harris Interactive and Toluna will also partner with leading French TV channel and radio station, M6 and RTL, throughout their coverage of the French elections. Harris Interactive and Toluna experts will first provide estimates of their weekly polling for the first and second rounds of the Presidential election, held Sunday, April 10, 2022, and Sunday, April 24, 2022.
The coverage will be live on M6 and RTL and will also be shared on Toluna and Harris Interactive social media networks from 12:00 PM CEST each election day and continuing throughout the day. The timeline will be as follows:
- 12:00 PM: Initial analysis of voter turnout
- 5:00 PM: Estimates of voter turnout
- 8:00 PM: Initial estimate of Presidential election results
- 8:30 PM onwards: Exclusive insights from “Voting Day” survey fielded by Harris Interactive and Toluna to understand voter motivations and abstentions
- Later in the evening: Refined results in real time
Following the Presidential election, Harris Interactive and Toluna will again work with M6 and RTL to deliver weekly polling for the French Legislative elections on June 12, 2022 and June 19, 2022, providing exclusive analysis and estimations of the French National Assembly’s composition.
The coverage will again feature live on M6 and RTL, available online throughout the evening, as well as on multiple social media channels, including:
- Harris Interactive: harris-interactive.fr / @HarrisInt_FR
- Toluna: tolunacorporate.com / @TolunaCorporate
- M6: groupem6.fr/ @M6, @M6Info, @M6Pro
- RTL: rtl.fr / @RTLFrance
Toluna CEO Frederic-Charles Petit, said: “We are thrilled to bring Toluna and Harris Interactive together to deliver our on-demand, real-time insights as part of this critical initiative in France’s political calendar. This is a great honor, and we look forward to delivering the accurate data the public desires.”
“Citizens today are bombarded with massive amounts of information during the election cycle, and it is essential that they have access to quality data as they evaluate candidates and results. For more than 20 years, Harris Interactive has been proud to deliver some of the most accurate measures of French election results, and we look forward to continuing this tradition in partnership with Toluna,” commented Jean-Daniel Lévy, Senior Vice President of Harris Interactive France and Director of Politics and Opinion Department.
About Toluna
Toluna delivers real-time consumer insights at the speed of the on-demand economy. Harris Interactive simplifies complex decisions with critical consumer intelligence. By fusing Harris’s sector expertise and award-winning research with Toluna’s innovative tools and technology, we strive to push market research toward a better tomorrow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom